Distinctive clinical and genetic features of lean vs overweight fatty liver disease using the UK Biobank - PubMed (original) (raw)

. 2022 Apr;16(2):325-336.

doi: 10.1007/s12072-022-10304-z. Epub 2022 Feb 18.

Affiliations

Distinctive clinical and genetic features of lean vs overweight fatty liver disease using the UK Biobank

Daljeet Chahal et al. Hepatol Int. 2022 Apr.

Abstract

Background: Lean NAFLD may differ from NAFLD found in overweight or obese patients. We used the UK biobank to conduct a cross-sectional study that examined features that distinguish lean NAFLD from overweight or obese NAFLD.

Methods: MRI-PDFF data were used to identify patients with NAFLD, with NAFLD defined as PDFF ≥ 5%. BMI patient cohorts were identified, with lean defined as a BMI < 25, and overweight or obese defined as a BMI ≥ 25. Variables of interest to fatty liver disease, including single nucleotide polymorphisms, were chosen from the UK biobank data portal. Logistic regression was used to generate models predictive of NAFLD in each cohort.

Results: 1007 patients had NAFLD, and of these, 871 had BMI ≥ 25, and 136 BMI < 25. Factors associated with NAFLD in patients with BMI < 25 included male sex, white blood cell count, red blood cell count, triglycerides, ALT, creatinine, visceral adipose tissue, rs58542926 T, and rs738409 G. In contrast, factors associated with NAFLD in patients with BMI ≥ 25 included male sex, waist circumference, HDL cholesterol, triglycerides, serum glucose, ALT, creatinine, urate, visceral adipose tissue, rs1260326 T, rs1044498 C, rs58542926 T, and rs738409 G. For lean patients, our generated prediction score had an AUC of 0.92, sensitivity of 0.90 and specificity of 0.81. For overweight or obese patients, the prediction score had an AUC of 0.86, sensitivity of 0.87 and specificity of 0.70.

Conclusions: Our analysis suggests that lean and overweight or obese NAFLD are distinct entities. We have developed a risk score incorporating both clinical and genetic factors that accurately classify lean patients with NAFLD, with the potential to serve as a tool for screening purposes.

Keywords: Cirrhosis; Diabetes; Fatty liver; Lean NASH; Liver; NAFLD; NASH; Obesity; Steatohepatitis; Transplant.

© 2022. Asian Pacific Association for the Study of the Liver.

PubMed Disclaimer

Comment in

References

    1. Younossi Z, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018;15:11 - DOI
    1. Yki-Järvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol 2014;2:901–910 - DOI
    1. Kesiraju S, Paritala P, Ch UMR, Sahariah S. New onset of diabetes after transplantation—an overview of epidemiology, mechanism of development and diagnosis. Transpl Immunol 2014;30:52–58 - DOI
    1. Wong RJ, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 2015;148:547–555 - DOI
    1. Chalasani N, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67:328–357 - DOI

MeSH terms

Substances

LinkOut - more resources